Sialoadenitis secondary to 131I therapy for well-differentiated thyroid cancer

Oral Diseases

Volumn 17, Issue 2, 2011, Pages 154-161

  Van Nostrand, D ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

131I, thyroid cancer; Sialoadenitis

Indexed keywords

AMIFOSTINE; ANTIINFLAMMATORY AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; ETHYNOL; IODINE 131; RADIOACTIVE IODINE; RESERPINE; SIALAGOGUE; UNCLASSIFIED DRUG; CHOLINERGIC RECEPTOR STIMULATING AGENT;

CANCER RADIOTHERAPY; CLINICAL FEATURE; DENTAL CARIES; DISEASE SEVERITY; HUMAN; HYDRATION; INCIDENCE; MASSAGE; PAROTID GLAND; PATIENT EDUCATION; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SALIVARY DUCT OBSTRUCTION; SIALOADENITIS; STOMATITIS; THYROID CANCER; TUMOR DIFFERENTIATION; XEROSTOMIA; RADIATION EXPOSURE; RADIATION INJURY; SALIVARY GLAND DUCT; SALIVATION; THYROID TUMOR;

CHOLINERGIC AGENTS; HUMANS; IODINE RADIOISOTOPES; RADIATION INJURIES; SALIVARY DUCTS; SALIVATION; SIALADENITIS; THYROID NEOPLASMS; XEROSTOMIA;

EID: 79951563380     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2010.01726.x     Document Type: Review

References (55)

1. Albrecht HH, Creutzig H (1976). Salivary gland scintigraphy after radioiodine therapy. Functional scintigraphy of the salivary gland after high dose radioiodine therapy. Fortschr Rontgenstr 125: 546-551.
2. Alexander C, Bader JB, Schaefer A, Finke C, Kirsh CM (1998). Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 39: 1551-1554.
3. Allweiss P, Braunstein GD, Katz A, Waxman A (1984). Sialadenitis following I-131 therapy for thyroid carcinoma: Concise communication. J Nucl Med 25: 755-758.
4. Benua RS, Cicale NR, Sonenberg M, Rawson RW (1962). The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 87: 171-182.
5. Blom M, Lunderberg T (2000). Long term follow up of patients treated with acupuncture for xerostomia and the influence of additional treatment. Oral Dis 6: 15-24.
6. Bohuslavizki KH, Klutmann S, Jenicke L, et al. (1999). Salivary gland protection by S-2-(3-amiopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double blind multi-arm trial. Cancer Biother Radiopharm 13: 337-347.
7. Bomeli SR, Schaitkin B, Carrau RL, Walvekar RR (2009). Interventional sialendoscopy for treating of radioiodine-induced sialadenitis. Laryngoscope 119: 864-867.
8. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL (1984). Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden hospital experience. Br J Radiol 57: 323-327.
9. Busnell DL, Boles MA, Kaufman GE, Wadas MA, Barnes WE (1992). Complications, sequela and dosimetry of iodine-131 therapy for thyroid carcinoma. J Nucl Med 33: 2214-2221.
10. Davies AN (1997). The management of xerostomia: a review. Eur J Cancer Care 6: 209-214.
11. Donachi I (1978). Biologic effects of radiation on the thyroid. In: Werner SC, Ingbar SH, eds The thyroid. Harper & Row: New York, pp. 274-283.
12. Dorr RT, Holmes BC (1999). Dosing considerations with amifostine: a review of the literature and clinical experience. Semin Oncol 26: 108-119.
13. Edmonds CJ, Smith T (1986). The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59: 45-51.
14. Ericson T, Lindberg A (1982). Clinical trial of a saliva stimulating tablet SST. Tandjakartidningen 74: 713-716.
15. Freinkel N, Ingbar SH (1953). Concentration gradients for inorganic I-131 and chloride in mixed human saliva. J Clin Invest 32: 1077-1084.
16. Goolden AWG, Mallard JR, Farran HEA (1957). Radiation sialitis following radioiodine therapy. Br J Radiol 30: 210-212.
17. Grewal RK, Larson SM, Pentlow CE, et al. (2009). Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 50: 1605-1610.
18. Hall P, Holm L-E, Lundell G, Ruden BI (1992). Tumors after radiotherapy for thyroid cancer. Acta Oncol 31: 403-407.
19. Hertz S, Roberts A (1942). Application of radioactive iodine in therapy of Graves' disease. J Clin Invest 1: 624.
20. Honour AJ, Myant NB, Rowland EN. (1952). Secretion of radioiodine in digestive juices and milk in man. Clin Sci 11: 447-462.
21. Jhiang SM, Cho JY, Ryu KY, et al. (1998). An immunohistochemical study of Na+/I-symporter in human thyroid tissues and salivary gland tissues. Endocrinology 139: 4416-4419.
22. Kahn S, Waxman A, Ramanna L, Ashok G, Nagaraq N, Braunstein G (1994). Transient radiation effects following high dose I-131 therapy for differentiated thyroid cancer (DTC). J Nucl Med 35: 15P.
23. Kim SJ, Choi HY, Kim IJ, et al. (2008). Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan. Thyroid 18: 325-331.
24. Kulkarni K, Kim SM, Intenzo C (2004). Can salivary gland uptakes on a diagnostic I-131 scan predict acute salivary gland dysfunction in patients receiving radioiodine therapy for thyroid cancer? J Nucl Med 5S: 291P.
25. Lam MGEH, van Isselt JW (2005). Does lemon candy decreased salivary gland damage after radioiodine therapy for thyroid cancer? Letter to the editor. J Nucl Med 46: 2118-2119.
26. Leeper R (1982). Controversies in the treatment of thyroid carcinoma: The New York Memorial Hospital approach. Thyroid Today 4: 1-6.
27. Levy HA, Park CH (1987). Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer. Clin Nucl Med 12: 303-307.
28. Lin WY, Shen YY, Wang SJ (1996). Short-term hazards of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients. Clin Nucl Med 21: 780-782.
29. Ma C, Xie J, Jiang X, Wang G, Zuo S (2010). Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging February 4, e-pub ahead of print.
30. Maier H, Bihl H (1987). Effect of radioactive iodine therapy on parotid gland function. Otolaryngology 103: 318-324.
31. Malpani BL, Samuel AM, Ray S (1996). Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. Int J Radiat Oncol Biol Phys 35: 535-540.
32. Mandel S, Mandel L (1999). Persistent Sialadenitis after radioactive iodine therapy: report of two cases. J Oral Maxillofac Surg 57: 738-741.
33. Mandel S, Mandel L (2003). Radioactive iodine and the salivary glands. Thyroid 13: 265-271.
34. Myant NB (1960). Iodine metabolism of salivary glands. Ann NY Acad Sci 85: 208.
35. Nakada K, Hirata K, Ishibashi T, et al. (2004). Cevimeline hydrochloride hydate in treating salivary gland dysfunction following radioiodine therapy for thyroid cancer. J Nucl Med 45S: 17P.
36. Nakada K, Ishibashi T, Takei T, et al. (2005). Dose lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 46: 261-266.
37. Pan MS (2004). Follow-up study of side effects for iodine-131 treatment in patients with differentiated thyroid cancer. J Nucl Med 5S: 386P.
38. Rice DH (1984). Advances in diagnosis and management of salivary gland diseases. [Medical Progress]. West J Med 140: 238-249.
39. Schiff L, Stevens CD, Molle WE, Steinberg H, Kumpe CW, Stewart P (1947). Gastric (and salivary) excretion of radioiodine in man (preliminary report). J Nat Cancer Inst 7: 349-354.
40. Schneyer LH, Tanchester D (1954). Some oral aspects of radioactive iodine therapy for thyroid disease. NYJ Dent 24: 308-309.
41. Seidlin SM, Marinelli LD, Oshry E (1946). Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 132: 838-847.
42. Shaw LM, Bonner HS, Schuchter L, Schiller J, Lierberman R (1999). Pharmacokinetics of amifostine: effects of dose and method of administration. Semin Oncol 26: 34-36.
43. Silberstein EB (2008). Reducing the incidence of 131-I-induced sialadenitis: The role of pilocarpine. J Nucl Med 49: 546-549.
44. Solans R, Bosch JA, Galofre P, et al. (2001). Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 42: 738-743.
45. Spiegel W, Reiners Chr, Borner W (1985). Sialadenitis following iodine-131 therapy for thyroid carcinoma. J Nucl Med 26: 816.
46. Tollefsen HR, DeCosse JJ, Hutter RVP (1964). Papillary carcinoma of the thyroid. A clinical and pathological study of 70 fatal cases. Cancer 17: 1035-1043.
47. Tubiana M, Lacour J, Monnier JP, et al. (1975). External radiotherapy and radioiodine in the treatment of 359 thyroid cancers. Br J Radiol 48: 894-907.
48. Utley JF, Phillips TL, Kane LJ (1976). Protection of normal tissues by WR-2721 during fractionated irradiation. AACN Clin Issues 1: 699-703.
49. Van Nostrand D, Atkins F, Bandaru VV, et al. (2009). Salivary gland protection with sialagogues. A Case Report. Thyroid 19: 1005-1008.
50. Van Nostrand D, Bandaru V, Chennupati V, et al. (2010). Reduction of radiation absorbed dose to the parotid glands after the administration of lemon juice. In press
51. Van Nostrand D, Freitas J (2006). Side effects of I-131 for ablation and treatment of well-differentiated thyroid carcinoma. In: Wartofsky L, Van Nostrand D, eds Thyroid Cancer: A Comprehensive Guide to Clinical Management. Humana Press: Totowa, New Jersey, pp. 459-484.
52. Van Nostrand DV, Neutze J, Atkins F (1986). Side effects of "rational dose" iodine-131 therapy for metastatic well differentiated thyroid carcinoma. J Nucl Med 27: 1519-1527.
53. Walter MA, Turtschi CP, Schinderl C, Mining P, Müller-Brand J., Müller B (2007). The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. J Nucl Med 48: 1620-1625.
54. Werner-Wasik M (1999). Future development of amifostine as a radioprotectant. Semin Oncol 26: 129-1234.
55. Xu JH, Su YX, Cheng MH, et al. (2010). Using Tc-99m pertechnetate scintigraphy to predict the outcome of sialendoscopy in obstructive submaxillaritis. Clin Nucl Med 35: 77-79.